Every day brings a new startup in the AI world! But today, at Yiaho, we’re excited because this startup is French: Synapse Medicine with its ambitious project, MedGPT. Launched as part of the France 2030 program and supported by Bpifrance, this young company aims to revolutionize medical assistance through specialized conversational AI.
While at Yiaho we have a multitude of AI agents, including an online medical advisor that can answer all your health questions, MedGPT is more B2B-oriented and intended directly for doctors themselves.
But can it really compete with giants like ChatGPT in the healthcare field?
MedGPT: A Medical AI Rooted in European Data
Contrary to what its name might suggest, MedGPT is not based on ChatGPT’s technology, but on the LLM (Large Language Model) developed by Mistral AI, another French startup. This choice is not random: by relying on a local model, Synapse Medicine ensures an approach adapted to European cultural and regulatory specificities, particularly regarding health data protection.
MedGPT stands out through its corpus of texts from French and European organizations. This medical database allows the AI to provide precise and contextualized answers, a major advantage over generalist models like a completely free ChatGPT, which rely on broader but sometimes less specialized data.
Two Innovative Modules for Healthcare Professionals
Synapse Medicine designed MedGPT with a clear objective: to make healthcare professionals’ daily work easier. The platform offers two flagship modules:
- Consultation Report: MedGPT generates clear and structured reports from exchanges between doctor and patient, reducing practitioners’ administrative burden.
- Medical Follow-up Summary: This module provides personalized recommendations to share with patients, improving communication and post-consultation follow-up.
These features, while simple in appearance, address a real need in the medical sector: optimizing caregivers’ time while improving the quality of patient interactions.
A Promising Beta Version… But Still Limited
Launched today in beta version, MedGPT is freely accessible with a limit of five questions per day. However, users will need to be patient: for now, the interface is only available in English and limited to a multiple-choice quiz mode.
The absence of a fully functional conversational interface could slow adoption in the short term, but Synapse Medicine may be surprised by the connection attempts since Tuesday, September 16 and the media coverage.
MedGPT vs ChatGPT: A Bold Comparison
So, can MedGPT really compete with ChatGPT in healthcare? While ChatGPT, particularly GPT-4o, excels through its versatility and ability to address a multitude of topics, it is not specifically designed for the medical sector. MedGPT, on the other hand, focuses on specialized expertise and increased reliability through its validated European data.
Here’s a quick comparison:
- Medical Accuracy: MedGPT, with its specialized corpus, offers more reliable answers for healthcare professionals, while ChatGPT can sometimes produce generalist or imprecise information in this field.
- Regulatory Compliance: MedGPT complies with strict European standards (notably GDPR and the AI Act), a decisive advantage over ChatGPT, which operates in a more global framework.
- Accessibility: ChatGPT benefits from a mature and multilingual interface, while MedGPT, still in beta, is limited to English and a multiple-choice mode.
A Promising Future for French Medical AI?
With MedGPT, Synapse Medicine lays the foundation for an ambitious French medical AI, capable of competing with international giants while meeting the specific needs of European professionals. While the current beta version shows some limitations, the potential is immense.
It remains to be seen whether the Bordeaux-based startup will succeed in delivering by offering a more intuitive interface and expanded features. One thing is certain: in the race for medical AI, France now has a card to play.
